NYSE - Delayed Quote USD

Baxter International Inc. (BAX)

Compare
33.91 +0.13 (+0.38%)
At close: June 17 at 4:00 PM EDT
33.40 -0.51 (-1.50%)
After hours: June 17 at 7:24 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
14,892,000.00
14,813,000.00
14,506,000.00
12,146,000.00
11,673,000.00
--
Cost of Revenue
9,805,000.00
9,838,000.00
9,440,000.00
7,426,000.00
7,086,000.00
--
Gross Profit
5,087,000.00
4,975,000.00
5,066,000.00
4,720,000.00
4,587,000.00
--
Operating Expense
4,666,000.00
4,563,000.00
4,435,000.00
3,384,000.00
3,036,000.00
--
Operating Income
421,000.00
412,000.00
631,000.00
1,336,000.00
1,551,000.00
--
Net Non Operating Interest Income Expense
-403,000.00
-442,000.00
-395,000.00
-193,000.00
-134,000.00
--
Other Income Expense
-20,000.00
-74,000.00
-2,886,000.00
-27,000.00
-125,000.00
--
Pretax Income
-1,000.00
-103,000.00
-2,650,000.00
1,116,000.00
1,292,000.00
--
Tax Provision
29,000.00
-34,000.00
4,000.00
83,000.00
182,000.00
--
Net Income Common Stockholders
2,649,000.00
2,656,000.00
-2,433,000.00
1,284,000.00
1,102,000.00
--
Diluted NI Available to Com Stockholders
2,649,000.00
2,656,000.00
-2,433,000.00
1,284,000.00
1,102,000.00
--
Basic EPS
5.23
5.25
-4.83
2.56
2.17
--
Diluted EPS
5.23
5.25
-4.83
2.53
2.13
--
Basic Average Shares
506,750.00
506,000.00
504,000.00
502,000.00
509,000.00
--
Diluted Average Shares
507,250.00
506,000.00
504,000.00
508,000.00
517,000.00
--
Total Operating Income as Reported
448,000.00
390,000.00
-2,243,000.00
1,350,000.00
1,616,000.00
--
Total Expenses
14,471,000.00
14,401,000.00
13,875,000.00
10,810,000.00
10,122,000.00
--
Net Income from Continuing & Discontinued Operation
2,649,000.00
2,656,000.00
-2,433,000.00
1,284,000.00
1,102,000.00
--
Normalized Income
-20,600.00
-23,070.00
-379,740.00
1,045,150.00
1,208,532.51
--
Interest Income
85,000.00
70,000.00
20,000.00
14,000.00
19,000.00
--
Interest Expense
488,000.00
512,000.00
415,000.00
207,000.00
153,000.00
--
Net Interest Income
-403,000.00
-442,000.00
-395,000.00
-193,000.00
-134,000.00
--
EBIT
487,000.00
409,000.00
-2,235,000.00
1,323,000.00
1,445,000.00
--
EBITDA
1,772,000.00
1,672,000.00
-855,000.00
2,190,000.00
2,268,000.00
--
Reconciled Cost of Revenue
9,805,000.00
9,838,000.00
9,440,000.00
7,426,000.00
7,086,000.00
--
Reconciled Depreciation
1,285,000.00
1,263,000.00
1,380,000.00
867,000.00
823,000.00
--
Net Income from Continuing Operation Net Minority Interest
-38,000.00
-76,000.00
-2,666,000.00
1,022,000.00
1,102,000.00
--
Total Unusual Items Excluding Goodwill
-29,000.00
-79,000.00
-2,894,000.00
-25,000.00
-124,000.00
--
Total Unusual Items
-29,000.00
-79,000.00
-2,894,000.00
-25,000.00
-124,000.00
--
Normalized EBITDA
1,801,000.00
1,751,000.00
2,039,000.00
2,215,000.00
2,392,000.00
--
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
--
Tax Effect of Unusual Items
-11,600.00
-26,070.00
-607,740.00
-1,850.00
-17,467.49
--
12/31/2019 - 10/27/1981

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BDX Becton, Dickinson and Company
232.75
-0.42%
 
HOLX Hologic, Inc.
71.43
-0.50%
 
XRAY DENTSPLY SIRONA Inc.
25.66
-1.72%
 
TFX Teleflex Incorporated
205.77
-1.21%
 
COO The Cooper Companies, Inc.
92.46
-1.08%
 
RMD ResMed Inc.
210.35
-0.65%
 
BLCO Bausch + Lomb Corporation
14.94
-0.99%
 
WST West Pharmaceutical Services, Inc.
336.08
+0.85%
 
EMBC Embecta Corp.
12.57
-1.80%
 
ANGO AngioDynamics, Inc.
5.89
-4.23%